<?xml version="1.0"?>
<!DOCTYPE TimeML SYSTEM "TimeML.dtd">
<TimeML>
Quest Diagnostics Incorporated (NYSE:DGX) – Equities researchers at SunTrust Banks lowered their Q1 2017 earnings estimates for shares of Quest Diagnostics in a report issued on <TIMEX3 tid="t2" type="DATE" value="2017-01-26">Thursday</TIMEX3>. SunTrust Banks analyst D. Macdonald <TIMEX3 tid="t5" type="DATE" value="PRESENT_REF">now</TIMEX3> forecasts that the brokerage will post earnings per share of $1.16 for <TIMEX3 tid="t4" type="DATE" value="2017-Q1">the quarter</TIMEX3>, down from their previous forecast of $1.21. SunTrust Banks also issued estimates for Quest Diagnostics’ Q3 2017 earnings at $1.45 EPS and Q4 2017 earnings at $1.41 EPS. 

Several other equities research analysts have also <TIMEX3 tid="t10" type="DATE" value="PAST_REF">recently</TIMEX3> weighed in on DGX. Canaccord Genuity set a $102.00 price objective on Quest Diagnostics and gave the stock a “buy” rating in a research note on <TIMEX3 tid="t11" type="DATE" value="2017-01-26">Thursday</TIMEX3>. Jefferies Group LLC upped their target price on Quest Diagnostics to $96.00 in a research note on <TIMEX3 tid="t12" type="DATE" value="2017-01-27">Friday</TIMEX3>. Zacks Investment Research raised Quest Diagnostics from a “hold” rating to a “buy” rating and set a $102.00 target price on the stock in a research note on <TIMEX3 tid="t15" type="DATE" value="2017-01-24">Tuesday, January 24th</TIMEX3>. Mizuho reaffirmed a “neutral” rating and set a $88.00 target price on shares of Quest Diagnostics in a research note on <TIMEX3 tid="t19" type="DATE" value="2017-11-30">Wednesday, November 30th</TIMEX3>. Finally, Barclays PLC set a $85.00 target price on Quest Diagnostics and gave the company a “hold” rating in a research note on <TIMEX3 tid="t23" type="DATE" value="2016-11-14">Monday, November 14th</TIMEX3>. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have given a buy rating to the company’s stock. The company <TIMEX3 tid="t25" type="DATE" value="PRESENT_REF">currently</TIMEX3> has an average rating of “Hold” and an average price target of $90.38.

TRADEMARK VIOLATION NOTICE: This article was posted by sleekmoney and is owned by of sleekmoney. If you are viewing this article on another site, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this article can be read at http://sleekmoney.com/suntrust-banks-comments-on-quest-diagnostics-incorporateds-q1-<TIMEX3 tid="t27" type="DATE" value="2017">2017</TIMEX3>-earnings-dgx/<TIMEX3 tid="t26" type="DATE" value="1630-12-8">1630128</TIMEX3>.html. 

Quest Diagnostics (NYSE:DGX) opened at 92.72 on <TIMEX3 tid="t28" type="DATE" value="2017-01-27">Friday</TIMEX3>. The company has a market cap of $12.85 billion, a price-to-earnings ratio of 19.68 and a beta of 0.66. The company’s <TIMEX3 tid="t29" type="DURATION" value="P50D">50-day</TIMEX3> moving average price is $92.18 and its <TIMEX3 tid="t30" type="DURATION" value="P200D">200-day</TIMEX3> moving average price is $86.17. Quest Diagnostics has a <TIMEX3 tid="t31" type="DURATION" value="P52W">52-week</TIMEX3> low of $59.66 and a <TIMEX3 tid="t32" type="DURATION" value="P52W">52-week</TIMEX3> high of $95.14. Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings data on <TIMEX3 tid="t35" type="DATE" value="2017-01-26">Thursday, January 26th</TIMEX3>. The company reported $1.31 earnings per share for <TIMEX3 tid="t37" type="DATE" value="2017-Q1">the quarter</TIMEX3>, beating the Zacks’ consensus estimate of $1.27 by $0.04. Quest Diagnostics had a return on equity of 14.62% and a net margin of 8.56%. The company earned $1.86 billion during <TIMEX3 tid="t38" type="DATE" value="2017-Q1">the quarter</TIMEX3>, compared to analyst estimates of $1.86 billion. During the same quarter <TIMEX3 tid="t39" type="DATE" value="2016">last year</TIMEX3>, the company earned $1.29 EPS. The firm’s revenue for <TIMEX3 tid="t40" type="DATE" value="2017-Q1">the quarter</TIMEX3> was up .6% on a year-over-year basis. 

Several hedge funds have <TIMEX3 tid="t44" type="DATE" value="PAST_REF">recently</TIMEX3> modified their holdings of the stock. American Century Companies Inc. raised its stake in shares of Quest Diagnostics by 27.7% in <TIMEX3 tid="t45" type="DATE" value="2016-Q2">the second quarter</TIMEX3>. American Century Companies Inc. <TIMEX3 tid="t48" type="DATE" value="PRESENT_REF">now</TIMEX3> owns 4,717,816 shares of the company’s stock valued at $384,077,000 after buying an additional 1,022,240 shares in <TIMEX3 tid="t47" type="DATE" value="2016-Q4">the last quarter</TIMEX3>. BlackRock Institutional Trust Company N.A. raised its stake in shares of Quest Diagnostics by 1.8% in <TIMEX3 tid="t49" type="DATE" value="2016-Q3">the third quarter</TIMEX3>. BlackRock Institutional Trust Company N.A. <TIMEX3 tid="t52" type="DATE" value="PRESENT_REF">now</TIMEX3> owns 4,265,792 shares of the company’s stock valued at $361,014,000 after buying an additional 77,423 shares in <TIMEX3 tid="t51" type="DATE" value="2016-Q4">the last quarter</TIMEX3>. BlackRock Advisors LLC raised its stake in shares of Quest Diagnostics by 3.1% in <TIMEX3 tid="t53" type="DATE" value="2016-Q3">the third quarter</TIMEX3>. BlackRock Advisors LLC <TIMEX3 tid="t56" type="DATE" value="PRESENT_REF">now</TIMEX3> owns 3,697,917 shares of the company’s stock valued at $312,955,000 after buying an additional 111,679 shares in <TIMEX3 tid="t55" type="DATE" value="2016-Q4">the last quarter</TIMEX3>. BlackRock Fund Advisors raised its stake in shares of Quest Diagnostics by 0.9% in <TIMEX3 tid="t57" type="DATE" value="2016-Q3">the third quarter</TIMEX3>. BlackRock Fund Advisors <TIMEX3 tid="t60" type="DATE" value="PRESENT_REF">now</TIMEX3> owns 3,088,078 shares of the company’s stock valued at $261,344,000 after buying an additional 28,019 shares in <TIMEX3 tid="t59" type="DATE" value="2016-Q4">the last quarter</TIMEX3>. Finally, Schroder Investment Management Group raised its stake in shares of Quest Diagnostics by 10.2% in <TIMEX3 tid="t61" type="DATE" value="2016-Q3">the third quarter</TIMEX3>. Schroder Investment Management Group <TIMEX3 tid="t64" type="DATE" value="PRESENT_REF">now</TIMEX3> owns 2,778,803 shares of the company’s stock valued at $235,171,000 after buying an additional 257,003 shares in <TIMEX3 tid="t63" type="DATE" value="2016-Q4">the last quarter</TIMEX3>. Hedge funds and other institutional investors own 87.71% of the company’s stock. 

TRADEMARK VIOLATION NOTICE: This article was posted by sleekmoney and is owned by of sleekmoney. If you are viewing this article on another site, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this article can be read at http://sleekmoney.com/suntrust-banks-comments-on-quest-diagnostics-incorporateds-q1-<TIMEX3 tid="t66" type="DATE" value="2017">2017</TIMEX3>-earnings-dgx/<TIMEX3 tid="t65" type="DATE" value="1630-12-8">1630128</TIMEX3>.html. 

The firm also <TIMEX3 tid="t70" type="DATE" value="PAST_REF">recently</TIMEX3> disclosed a quarterly dividend, which was paid on <TIMEX3 tid="t69" type="DATE" value="2017-01-25">Wednesday, January 25th</TIMEX3>. Stockholders of record on <TIMEX3 tid="t74" type="DATE" value="2017-01-10">Tuesday, January 10th</TIMEX3> were issued a dividend of $0.45 per share. This represents a $1.80 annualized dividend and a dividend yield of 1.94%. The ex-dividend date was <TIMEX3 tid="t78" type="DATE" value="2017-01-06">Friday, January 6th</TIMEX3>. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.40. Quest Diagnostics’s dividend payout ratio is <TIMEX3 tid="t80" type="DATE" value="PRESENT_REF">currently</TIMEX3> 40.00%. 

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Company’s Diagnostic Information Services business develops and delivers diagnostic testing information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, employers and others.
</TimeML>
